Literature DB >> 27567593

Progestin-only contraceptives: effects on weight.

Laureen M Lopez1, Shanthi Ramesh, Mario Chen, Alison Edelman, Conrad Otterness, James Trussell, Frans M Helmerhorst.   

Abstract

BACKGROUND: Progestin-only contraceptives (POCs) are appropriate for many women who cannot or should not take estrogen. POCs include injectables, intrauterine contraception, implants, and oral contraceptives. Many POCs are long-acting, cost-effective methods of preventing pregnancy. However, concern about weight gain can deter the initiation of contraceptives and cause early discontinuation among users.
OBJECTIVES: The primary objective was to evaluate the association between progestin-only contraceptive use and changes in body weight. SEARCH
METHODS: Until 4 August 2016, we searched MEDLINE, CENTRAL, POPLINE, LILACS, ClinicalTrials.gov, and ICTRP. For the initial review, we contacted investigators to identify other trials. SELECTION CRITERIA: We considered comparative studies that examined a POC versus another contraceptive method or no contraceptive. The primary outcome was mean change in body weight or mean change in body composition. We also considered the dichotomous outcome of loss or gain of a specified amount of weight. DATA COLLECTION AND ANALYSIS: Two authors extracted the data. Non-randomized studies (NRS) need to control for confounding factors. We used adjusted measures for the primary effects in NRS or the results of matched analysis from paired samples. If the report did not provide adjusted measures for the primary analysis, we used unadjusted outcomes. For RCTs and NRS without adjusted measures, we computed the mean difference (MD) with 95% confidence interval (CI) for continuous variables. For dichotomous outcomes, we calculated the Mantel-Haenszel odds ratio (OR) with 95% CI. MAIN
RESULTS: We found 22 eligible studies that included a total of 11,450 women. With 6 NRS added to this update, the review includes 17 NRS and 5 RCTs. By contraceptive method, the review has 16 studies of depot medroxyprogesterone acetate (DMPA), 4 of levonorgestrel-releasing intrauterine contraception (LNG-IUC), 5 for implants, and 2 for progestin-only pills.Comparison groups did not differ significantly for weight change or other body composition measure in 15 studies. Five studies with moderate or low quality evidence showed differences between study arms. Two studies of a six-rod implant also indicated some differences, but the evidence was low quality.Three studies showed differences for DMPA users compared with women not using a hormonal method. In a retrospective study, weight gain (kg) was greater for DMPA versus copper (Cu) IUC in years one (MD 2.28, 95% CI 1.79 to 2.77), two (MD 2.71, 95% CI 2.12 to 3.30), and three (MD 3.17, 95% CI 2.51 to 3.83). A prospective study showed adolescents using DMPA had a greater increase in body fat (%) compared with a group not using a hormonal method (MD 11.00, 95% CI 2.64 to 19.36). The DMPA group also had a greater decrease in lean body mass (%) (MD -4.00, 95% CI -6.93 to -1.07). A more recent retrospective study reported greater mean increases with use of DMPA versus Cu IUC for weight (kg) at years 1 (1.3 vs 0.2), 4 (3.5 vs 1.9), and 10 (6.6 vs 4.9).Two studies reported a greater mean increase in body fat mass (%) for POC users versus women not using a hormonal method. The method was LNG-IUC in two studies (reported means 2.5 versus -1.3; P = 0.029); (MD 1.60, 95% CI 0.45 to 2.75). One also studied a desogestrel-containing pill (MD 3.30, 95% CI 2.08 to 4.52). Both studies showed a greater decrease in lean body mass among POC users. AUTHORS'
CONCLUSIONS: We considered the overall quality of evidence to be low; more than half of the studies had low quality evidence. The main reasons for downgrading were lack of randomizations (NRS) and high loss to follow-up or early discontinuation.These 22 studies showed limited evidence of change in weight or body composition with use of POCs. Mean weight gain at 6 or 12 months was less than 2 kg (4.4 lb) for most studies. Those with multiyear data showed mean weight change was approximately twice as much at two to four years than at one year, but generally the study groups did not differ significantly. Appropriate counseling about typical weight gain may help reduce discontinuation of contraceptives due to perceptions of weight gain.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27567593      PMCID: PMC5034734          DOI: 10.1002/14651858.CD008815.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  89 in total

1.  Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.

Authors:  Carolyn Westhoff; John K Jain; Ian Milsom; Amrit Ray
Journal:  Contraception       Date:  2007-02-23       Impact factor: 3.375

2.  Factors associated with lack of effective contraception among obese women in the United States.

Authors:  Lisa S Callegari; Karin M Nelson; David E Arterburn; Sarah W Prager; Melissa A Schiff; Eleanor Bimla Schwarz
Journal:  Contraception       Date:  2014-05-14       Impact factor: 3.375

3.  [Experience with contraceptive effect of Depo-Provera, 300mg and 450mg, administered in 6-month intervals].

Authors:  F Havránek; M Tichý; F Divila; V Hejda
Journal:  Cesk Gynekol       Date:  1972-03

4.  Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.

Authors:  Andrea E Bonny; Julie Ziegler; Ray Harvey; Sara M Debanne; Michelle Secic; Barbara A Cromer
Journal:  Arch Pediatr Adolesc Med       Date:  2006-01

5.  Weight change at 12 months in users of three progestin-only contraceptive methods.

Authors:  Zevidah Vickery; Tessa Madden; Qiuhong Zhao; Gina M Secura; Jenifer E Allsworth; Jeffrey F Peipert
Journal:  Contraception       Date:  2013-03-18       Impact factor: 3.375

6.  Prevalence of childhood and adult obesity in the United States, 2011-2012.

Authors:  Cynthia L Ogden; Margaret D Carroll; Brian K Kit; Katherine M Flegal
Journal:  JAMA       Date:  2014-02-26       Impact factor: 56.272

7.  The Effect of Depo Medroxyprogesterone Acetate (DMPA) on Cerebral Food Motivation Centers: A Pilot Study using Functional Magnetic Resonance Imaging.

Authors:  Tania Basu; Pinglei Bao; Alexander Lerner; Lindsey Anderson; Kathleen Page; Frank Stanczyk; Daniel Mishell; Penina Segall-Gutierrez
Journal:  Contraception       Date:  2016-04-27       Impact factor: 3.375

Review 8.  Progestogen-only contraceptive use in obese women.

Authors:  Kathryn M Curtis; Anita Ravi; Mary Lyn Gaffield
Journal:  Contraception       Date:  2009-06-10       Impact factor: 3.375

9.  [Clinic observation of a levonorgestrel-releasing intrauterine system inserted immediately after artificial abortion].

Authors:  Jing Chen; Xian-jing Wang; Yan Liang; Qin Jin
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2011-12-06

10.  Acceptability of injectable contraceptives in Assiut, Egypt.

Authors:  H T Salem; M Salah; M Y Aly; A I Thabet; M M Shaaban; M F Fathalla
Journal:  Contraception       Date:  1988-12       Impact factor: 3.375

View more
  16 in total

1.  Oral contraceptive use and fracture risk-a retrospective study of 12,970 women in the UK.

Authors:  S Dombrowski; L Jacob; P Hadji; K Kostev
Journal:  Osteoporos Int       Date:  2017-04-13       Impact factor: 4.507

2.  Oral Contraceptives and Cigarette Smoking: A Review of the Literature and Future Directions.

Authors:  Alicia M Allen; Andrea H Weinberger; Reagan R Wetherill; Carol L Howe; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2019-04-17       Impact factor: 4.244

3.  An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users.

Authors:  Aaron Lazorwitz; Eva Dindinger; Margaret Harrison; Christina L Aquilante; Jeanelle Sheeder; Stephanie Teal
Journal:  Contraception       Date:  2020-05-12       Impact factor: 3.375

Review 4.  New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services.

Authors:  David K Turok; Lori M Gawron; Samantha Lawson
Journal:  Fertil Steril       Date:  2016-10-04       Impact factor: 7.329

5.  Preliminary side effect profile, safety, and tolerability of hormonal contraception among women receiving opioid-agonist therapy.

Authors:  Heidi S Melbostad; Deborah S Wachtel; Kerstin A Lipke; Gary J Badger; Alexis K Matusiewicz; Catalina N Rey; Lauren K MacAfee; Anne K Dougherty; Sarah H Heil
Journal:  Contraception       Date:  2022-03-11       Impact factor: 3.051

6.  A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.

Authors:  Aikaterini A Nella; Ashwini Mallappa; Ashley F Perritt; Verena Gounden; Parag Kumar; Ninet Sinaii; Lori-Ann Daley; Alexander Ling; Chia-Ying Liu; Steven J Soldin; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2016-09-28       Impact factor: 5.958

7.  Hormonally Active Contraceptives Part I: Risks Acknowledged and Unacknowledged.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Mike Gaskins; Elvis I Seman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-01-27

Review 8.  Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.

Authors:  Sneha Singh; Maria L Ricardo-Silgado; Suzette J Bielinski; Andres Acosta
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 5.002

9.  Prevalence and Predictors of Overweight and Obesity Among Kenyan Women.

Authors:  Rahma S Mkuu; Katrina Epnere; Muhammad Abdul Baker Chowdhury
Journal:  Prev Chronic Dis       Date:  2018-04-19       Impact factor: 2.830

10.  Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis.

Authors:  Marija Glisic; Sara Shahzad; Stergiani Tsoli; Mahmuda Chadni; Eralda Asllanaj; Lyda Z Rojas; Elizabeth Brown; Rajiv Chowdhury; Taulant Muka; Oscar H Franco
Journal:  Eur J Prev Cardiol       Date:  2018-05-10       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.